STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
The structure was published by Cui, J.J., Tran-Dube, M., Shen, H., et al., Bender, S., Kania, R.S., and Edwards, M.P., in 2011 in a paper entitled "Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-met) Kinase and Anaplastic Lymphoma Kinase (Alk)." (abstract).
This crystal structure was determined using X-ray diffraction at a resolution of 1.9 Å and deposited in 2010.
The experimental data on which the structure is based was also deposited.
The PDB entry contains the structure of TYROSINE-PROTEIN KINASE RECEPTOR. This molecule has the UniProt identifier Q9UM73 (ALK_HUMAN). The sample contained 327 residues which is < 90% of the natural sequence. Out of 327 residues 285 were observed and are deposited in the PDB.
It also contains one or more heterogenic compounds (e.g., ligands, co-factors, ions, modified amino acids, etc.); see here for a complete list.
The molecule is most likely monomeric.
The following tables show cross-reference information to other databases (to obtain a list of all PDB entries sharing the same property or classification, click on the magnifying glass icon):
This entry contains 1 unique UniProt protein: